Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
Contraception
Copper intrauterine device
Depot medroxyprogesterone acetate
Free testosterone
Levonorgestrel implant
Randomized trial
Sex hormone binding globulin
Testosterone
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
received:
07
03
2022
accepted:
22
02
2024
medline:
9
3
2024
pubmed:
9
3
2024
entrez:
8
3
2024
Statut:
epublish
Résumé
Robust information on relative effects of hormonal contraceptives on endogenous androgens is important for understanding beneficial and adverse effects, method choice and development of new methods. In this ancillary study at the East London, South Africa site of the ECHO multicentre randomized trial, we compared effects of three contraceptive methods on serum androgen levels among contraceptive users aged 18 to 35 years. Participants were allocated by centrally-managed randomization to open label depot medroxyprogesterone acetate (DMPA-IM), copper intrauterine device (IUD) or levonorgestrel implant. The primary outcome was free testosterone at 6 months. We analysed stored baseline and 6-month serum samples in 398/615 participants (DMPA-IM 131/205, IUD 135/205 and implant 132/205). Median testosterone levels at baseline were DMPA-IM 0.82, IUD 0.9 and implant 0.87 nmol/L; at 6 months, DMPA 0.68 (lower than IUD, mean percentage difference 28.35, (p < 0.001), IUD 0.86 (unchanged) and implant 0.66, lower than IUD, mean percentage difference - 22.98, p < 0.001). Median SHBG levels at baseline were DMPA 52.4, IUD 50.5 and implant 55.75 nmol/L; at 6 months, DMPA 40.65, lower than IUD (mean percentage difference 21.19, p = 0.005), IUD 49.1 (unchanged), and implant 23.35 nmol/L, lower than IUD (mean percentage difference - 50.04, p < 0.001 and than DMPA (mean percentage difference - 39.45, p < 0.001). Free testosterone levels at baseline were DMPA 10, IUD 12 and implant 11 pmol/L; at 6 months, DMPA 11, less than IUD (mean percentage difference 13.53, p = 0.047), IUD 12 and implant 14, higher than IUD (mean percentage difference 14.15, p = 0.038) and than DMPA, (mean percentage difference 29.60, p < 0.001). This is the first randomized trial to show lower SHBG and higher free testosterone with the levonorgestrel implant than with DMPA, and contrasts with reports of increased SHBG with combined oral ethinyl estradiol/levonorgestrel use, and reduced androgens (and impaired sexual function) reported with the etonorgestrel implant. The higher free testosterone with the LNG implant might improve sexual function, mood and bone health as well as increasing side-effects such as acne and hirsutism, and is consistent with the greater sexual activity (with respect to multiple sex partners, new sex partner and unprotected sex) with the implant compared with DMPA documented in the ECHO study. ClinicalTrials.gov , number NCT02550067 15/09/2015. Contraception, or family planning, is central to the role of women in societies. It is most important to have accurate information on the relative side-effects of various contraceptive options in order to empower women to make informed choices regarding their preferred method. Hormonal contraceptives contain various forms of the female sex hormones, estrogens and/or progestogens. These hormones have direct effects on the users, as well as modifying the levels of the users' own circulating sex hormones, both the 'female' and the 'male' sex hormones (androgens). In this study, consenting participants requesting contraception, were allocated randomly to receive either depot medroxyprogesterone acetate (DMPA-IM) a 3-monthly progestogen injection, the copper intrauterine device (IUD), a non-hormonal contraceptive inserted within the womb, or the levonorgestrel implant, a device placed under the skin which releases a progestogen for 5 years. We measured the participants' androgen levels after 6 months, and found for the first time that the active form of testosterone (free testosterone) was 29% higher with the implant than with DMPA-IM. The level with the IUD was intermediate, and significantly different from the other two methods. This finding is relevant to the effects experienced by users of these methods, because free testosterone has effects on sexual function, bone health and mood, as well as on conditions such as acne and hair distribution patterns.
Sections du résumé
BACKGROUND
BACKGROUND
Robust information on relative effects of hormonal contraceptives on endogenous androgens is important for understanding beneficial and adverse effects, method choice and development of new methods.
METHODS
METHODS
In this ancillary study at the East London, South Africa site of the ECHO multicentre randomized trial, we compared effects of three contraceptive methods on serum androgen levels among contraceptive users aged 18 to 35 years. Participants were allocated by centrally-managed randomization to open label depot medroxyprogesterone acetate (DMPA-IM), copper intrauterine device (IUD) or levonorgestrel implant. The primary outcome was free testosterone at 6 months.
RESULTS
RESULTS
We analysed stored baseline and 6-month serum samples in 398/615 participants (DMPA-IM 131/205, IUD 135/205 and implant 132/205). Median testosterone levels at baseline were DMPA-IM 0.82, IUD 0.9 and implant 0.87 nmol/L; at 6 months, DMPA 0.68 (lower than IUD, mean percentage difference 28.35, (p < 0.001), IUD 0.86 (unchanged) and implant 0.66, lower than IUD, mean percentage difference - 22.98, p < 0.001). Median SHBG levels at baseline were DMPA 52.4, IUD 50.5 and implant 55.75 nmol/L; at 6 months, DMPA 40.65, lower than IUD (mean percentage difference 21.19, p = 0.005), IUD 49.1 (unchanged), and implant 23.35 nmol/L, lower than IUD (mean percentage difference - 50.04, p < 0.001 and than DMPA (mean percentage difference - 39.45, p < 0.001). Free testosterone levels at baseline were DMPA 10, IUD 12 and implant 11 pmol/L; at 6 months, DMPA 11, less than IUD (mean percentage difference 13.53, p = 0.047), IUD 12 and implant 14, higher than IUD (mean percentage difference 14.15, p = 0.038) and than DMPA, (mean percentage difference 29.60, p < 0.001).
CONCLUSIONS
CONCLUSIONS
This is the first randomized trial to show lower SHBG and higher free testosterone with the levonorgestrel implant than with DMPA, and contrasts with reports of increased SHBG with combined oral ethinyl estradiol/levonorgestrel use, and reduced androgens (and impaired sexual function) reported with the etonorgestrel implant. The higher free testosterone with the LNG implant might improve sexual function, mood and bone health as well as increasing side-effects such as acne and hirsutism, and is consistent with the greater sexual activity (with respect to multiple sex partners, new sex partner and unprotected sex) with the implant compared with DMPA documented in the ECHO study.
ECHO TRIAL REGISTRATION
UNASSIGNED
ClinicalTrials.gov , number NCT02550067 15/09/2015. Contraception, or family planning, is central to the role of women in societies. It is most important to have accurate information on the relative side-effects of various contraceptive options in order to empower women to make informed choices regarding their preferred method. Hormonal contraceptives contain various forms of the female sex hormones, estrogens and/or progestogens. These hormones have direct effects on the users, as well as modifying the levels of the users' own circulating sex hormones, both the 'female' and the 'male' sex hormones (androgens). In this study, consenting participants requesting contraception, were allocated randomly to receive either depot medroxyprogesterone acetate (DMPA-IM) a 3-monthly progestogen injection, the copper intrauterine device (IUD), a non-hormonal contraceptive inserted within the womb, or the levonorgestrel implant, a device placed under the skin which releases a progestogen for 5 years. We measured the participants' androgen levels after 6 months, and found for the first time that the active form of testosterone (free testosterone) was 29% higher with the implant than with DMPA-IM. The level with the IUD was intermediate, and significantly different from the other two methods. This finding is relevant to the effects experienced by users of these methods, because free testosterone has effects on sexual function, bone health and mood, as well as on conditions such as acne and hair distribution patterns.
Identifiants
pubmed: 38459552
doi: 10.1186/s12905-024-02990-8
pii: 10.1186/s12905-024-02990-8
doi:
Banques de données
ClinicalTrials.gov
['NCT02550067']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
167Informations de copyright
© 2024. The Author(s).
Références
Bosanac SS, Trivedi M, Clark AK, Sivamani RK, Larsen LN. Progestins and acne vulgaris: a review. Dermatol Online J. 2018;24(5):13030.
doi: 10.5070/D3245040035
Jones EE. Androgenic effects of oral contraceptives: implications for patient compliance. Am J Med. 1995;98(1A):116S–9S.
doi: 10.1016/S0002-9343(99)80069-2
pubmed: 7825631
De Leo V, Musacchio MC, Cappelli V, Piomboni P, Morgante G. Hormonal contraceptives: pharmacology tailored to women's health. Hum Reprod Update. 2016;22(5):634–46.
doi: 10.1093/humupd/dmw016
pubmed: 27307386
Bancroft J, Sartorius N. The effects of oral contraceptives on well-being and sexuality. Oxf Rev Reprod Biol. 1990;12:57–92.
pubmed: 2075004
Evans SF, Kwok Y, Solterbeck A, Pyragius C, Hull ML, Hutchinson MR, et al. The relationship between androgens and days per month of period pain, pelvic pain, headache, and TLR4 responsiveness of peripheral blood mononuclear cells in young women with Dysmenorrhoea. J Pain Res. 2021;14:585–99.
doi: 10.2147/JPR.S279253
pubmed: 33688248
pmcid: 7937378
van Lunsen RHW, Zimmerman Y, Coelingh Bennink HJT, Termeer HMM, Appels N, Fauser BCJM, et al. Maintaining physiologic testosterone levels during combined oral contraceptives by adding dehydroepiandrosterone: II. Effects on sexual function. A phase II randomized, double-blind, placebo-controlled study. Contra. 2018;98(1):56–62.
doi: 10.1016/j.contraception.2018.02.014
Vegunta S, Kling JM, Kapoor E. J androgen therapy in women. Womens Health (Larchmt). 2020;29(1):57–64.
doi: 10.1089/jwh.2018.7494
Coelingh Bennink HJT, Zimmerman Y, Laan E, Termeer HMM, Appels N, Albert A, et al. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endoc Eff Contra. 2017;96(5):322–32.
Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Temmerman M. Hypothesis: amenorrhea-inducing contraception may reduce HIV acquisition risk. Contra. 2014;90(6):615–6.
doi: 10.1016/j.contraception.2014.09.005
Hofmeyr GJ, Singata M, Lawrie TA, Temmerman M. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk. Lancet HIV. 2015;2(9):e365.
doi: 10.1016/S2352-3018(15)00153-8
pubmed: 26423546
Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial. Reprod Health. 2016;13(1):42.
doi: 10.1186/s12978-016-0153-9
pubmed: 27091008
pmcid: 4835872
Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M. Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. J Fam Plann Reprod Health Care. 2017;43(3):175–80.
doi: 10.1136/jfprhc-2016-101607
pubmed: 28381443
pmcid: 5537534
Ahmed K, Baeten JM, Beksinska M, Bekker LG, Bukusi EA, Donnell D, Gichangi PB, Heller KB, Hofmeyr GJ, Justman J, Kasaro MP. The evidence for contraceptive options and HIV outcomes (ECHO) trial consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomized, open-label clinical trial. Lancet. 2019;394:303–13.
doi: 10.1016/S0140-6736(19)31288-7
Segall-Gutierrez P, Du J, Niu C, Ge M, Tilley I, Mizraji K, et al. Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women. Contra. 2012;86(6):739–4.
doi: 10.1016/j.contraception.2012.05.148
Schaffir JA, Isley MM, Woodward M. Oral contraceptives vs injectable progestin in their effect on sexual behavior. Am J Obstet Gynecol. 2010;203(6):545.e1–5.
doi: 10.1016/j.ajog.2010.07.024
pubmed: 20800828
Moreira IFA, Bianchini MP, Moreira GRC, Almeida AM, Rezende BA. Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study. BMC Womens Health. 2020;20(1):240.
doi: 10.1186/s12905-020-01107-1
pubmed: 33109159
pmcid: 7590685
Hofmeyr GJ, Morrison CS, Baeten JM, Chipato T, Donnell D, Gichangi P, et al. Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study). Gates Open Res. 2017;29(1):17. https://doi.org/10.12688/gatesopenres.12775.1 .
doi: 10.12688/gatesopenres.12775.1
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–72. https://doi.org/10.1210/jcem.84.10.6079 . PMID: 10523012
doi: 10.1210/jcem.84.10.6079
pubmed: 10523012
Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA, Heijboer AC. Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS/MS method and a 2nd generation automated immunoassay. Steroids. 2013;78(1):96–101.
doi: 10.1016/j.steroids.2012.10.010
pubmed: 23127814
Williams NM, Randolph M, Rajabi-Estarabadi A, Keri J, Tosti A. Hormonal contraceptives and dermatology. Am J Clin Dermatol. 2020;22:69–80. https://doi.org/10.1007/s40257-020-00557-5 .
doi: 10.1007/s40257-020-00557-5
Deese J, Lien Chen P, Gao X, Heffron R, Miller A, Steiner M, et al. Post-randomization differences in condomless vaginal sex among women randomized to DMPA-IM, copper IUD and levonorgestrel implant in the ECHO trial. J Int AIDS Soc. 2021;24(S1):e25659.
Zhao XJ, Shao GX, Zhang J, Sang GW. Effects of steroid contraceptive on serum levels of sex hormone binding globulin in women. Shengzhi Yu Biyun. 1992;12(4):13–7.
pubmed: 12286664
Achilles SL, Mhlanga FG, Musara P, Poloyac SM, Chirenje ZM, Hillier SL. Misreporting of contraceptive hormone use in clinical research participants. Contra. 2018;97(4):346–53.
doi: 10.1016/j.contraception.2017.09.013